Hyo-In Yun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hyo-In Yun has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
In-Bae Song
Lab of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Chungnam National University, Daejeon, Korea
7 shared publicationsMyoung-Seok Kim
Jeollanamdo Development Institute for Traditional Korean Medicine, Jangheung, Jeollanam-Do, Korea
7 shared publicationsJong-Hwan Lim
B&C Biopharm, Advanced Institutes of Convergence Technology, Suwon-si, Gyonggi-do, Korea
6 shared publicationsB.‐K. Park
JEONJINBIO, Techno Park Venture Factory of Daegu, Daegu, Korea
5 shared publicationsJ.‐H. Lim
B&C Biopharm, Advanced Institutes of Convergence Technology, Gyeonggi-do, Korea
5 shared publicationsByung-Kwon Park
JEONJINBIO, Technopark Venture Factory of Daegu, 711 Hosan-dong, Daegu, 704-230, Korea
4 shared publications
Latest Publications
- 1 September 2015
- Published by Elsevier in European Journal of Pharmacology
- Vol. 762, 350-356
Synergistic interaction between tapentadol and flupirtine in the rat orafacial formalin test
- 1 September 2015
- Published by Elsevier in European Journal of Pharmacology
- Vol. 762, 350-356
Synergistic interaction between tapentadol and flupirtine in the rat orafacial formalin test
- Open Access
- 1 December 2014
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 9, 109-26
Toxicity of 100 nm zinc oxide nanoparticles: a report of 90-day repeated oral administration in Sprague Dawley rats
Nanoparticles (NPs) are used commercially in health and fitness fields, but information about the toxicity and mechanisms underlying the toxic effects of NPs is still very limited. The aim of this study is to investigate the toxic effect(s) of 100 nm negatively (ZnOAE100[-]) or positively (ZnOAE100[+]) charged zinc oxide (ZnO) NPs administered by gavage in Sprague Dawley rats, to establish a no observed adverse effect level, and to identify target organ(s). After verification of the primary particle size, morphology, hydrodynamic size, and zeta potential of each test article, we performed a 90-day study according to Organisation for Economic Co-operation and Development test guideline 408. For the 90-day study, the high dose was set at 500 mg/kg and the middle and low doses were set at 125 mg/kg and 31.25 mg/kg, respectively. Both ZnO NPs had significant changes in hematological and blood biochemical analysis, which could correlate with anemia-related parameters, in the 500 mg/kg groups of both sexes. Histopathological examination showed significant adverse effects (by both test articles) in the stomach, pancreas, eye, and prostate gland tissues, but the particle charge did not affect the tendency or the degree of the lesions. We speculate that this inflammatory damage might result from continuous irritation caused by both test articles. Therefore, the target organs for both ZnOAE100(-) and ZnOAE100(+) are considered to be the stomach, pancreas, eye, and prostate gland. Also, the no observed adverse effect level for both test articles was identified as 31.25 mg/kg for both sexes, because the adverse effects were observed at all doses greater than 125 mg/kg.
- 1 December 2014
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. 9, 109-26
Open AccessToxicity of 100 nm zinc oxide nanoparticles: a report of 90-day repeated oral administration in Sprague Dawley rats
Nanoparticles (NPs) are used commercially in health and fitness fields, but information about the toxicity and mechanisms underlying the toxic effects of NPs is still very limited. The aim of this study is to investigate the toxic effect(s) of 100 nm negatively (ZnOAE100[-]) or positively (ZnOAE100[+]) charged zinc oxide (ZnO) NPs administered by gavage in Sprague Dawley rats, to establish a no observed adverse effect level, and to identify target organ(s). After verification of the primary particle size, morphology, hydrodynamic size, and zeta potential of each test article, we performed a 90-day study according to Organisation for Economic Co-operation and Development test guideline 408. For the 90-day study, the high dose was set at 500 mg/kg and the middle and low doses were set at 125 mg/kg and 31.25 mg/kg, respectively. Both ZnO NPs had significant changes in hematological and blood biochemical analysis, which could correlate with anemia-related parameters, in the 500 mg/kg groups of both sexes. Histopathological examination showed significant adverse effects (by both test articles) in the stomach, pancreas, eye, and prostate gland tissues, but the particle charge did not affect the tendency or the degree of the lesions. We speculate that this inflammatory damage might result from continuous irritation caused by both test articles. Therefore, the target organs for both ZnOAE100(-) and ZnOAE100(+) are considered to be the stomach, pancreas, eye, and prostate gland. Also, the no observed adverse effect level for both test articles was identified as 31.25 mg/kg for both sexes, because the adverse effects were observed at all doses greater than 125 mg/kg.
- 12 September 2013
- Published by Wiley in Journal of Applied Toxicology
- Vol. 34 (12) , 1271-1284
CKD‐501, a novel selective PPARγ agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks
CKD‐501 is a peroxisome proliferator‐activated receptor gamma (PPARγ) agonist that is effective for the treatment of diabetes. However, its carcinogenic potential remains controversial. The current carcinogenicity study was conducted over a period of 104 weeks in ICR mice. Three groups, each consisting of 60 male and 60 female mice, received oral CKD‐501 dosages of 0.2, 1.0 or 6.0 mg kg−1day–1. The mortality rates of the male control, 0.2, 1.0 and 6.0 mg kg–1 day–1 treated groups were 60%, 68%, 58% and 67%, respectively and 57%, 68% and 67% in the female control, 0.2 and 1.0 mg kg−1 day–1 treated groups. It was 67% in the female 6.0 mg kg−1 day–1 treated group, which was terminated at week 98 due to its increased mortality rate. No significant treatment‐related effects were observed on the survival rates, with the exception of females in the 6.0 mg kg−1 day–1 group. Body weights increased in females receiving 1.0 and 6.0 mg kg−1 day–1 due to the class effects of the PPARγ agonist. Differences were not found in hematology parameters between the CKD‐501‐treated groups and their corresponding controls, but the histopathological evidence did not reveal any findings attributed to CKD‐501. Treated animals exhibited non‐neoplastic findings (adipocyte proliferation, bone marrow hypoplasia cardiomyopathy), but all of these were expected changes for this class of compound. There were no treatment‐related neoplastic changes in this study. The results of this study therefore demonstrate a lack of carcinogenicity following oral administration of CKD‐501 to ICR mice for 104 weeks. Copyright © 2013 John Wiley & Sons, Ltd.
- 12 September 2013
- Published by Wiley in Journal of Applied Toxicology
- Vol. 34 (12) , 1271-1284
CKD‐501, a novel selective PPARγ agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks
CKD‐501 is a peroxisome proliferator‐activated receptor gamma (PPARγ) agonist that is effective for the treatment of diabetes. However, its carcinogenic potential remains controversial. The current carcinogenicity study was conducted over a period of 104 weeks in ICR mice. Three groups, each consisting of 60 male and 60 female mice, received oral CKD‐501 dosages of 0.2, 1.0 or 6.0 mg kg−1day–1. The mortality rates of the male control, 0.2, 1.0 and 6.0 mg kg–1 day–1 treated groups were 60%, 68%, 58% and 67%, respectively and 57%, 68% and 67% in the female control, 0.2 and 1.0 mg kg−1 day–1 treated groups. It was 67% in the female 6.0 mg kg−1 day–1 treated group, which was terminated at week 98 due to its increased mortality rate. No significant treatment‐related effects were observed on the survival rates, with the exception of females in the 6.0 mg kg−1 day–1 group. Body weights increased in females receiving 1.0 and 6.0 mg kg−1 day–1 due to the class effects of the PPARγ agonist. Differences were not found in hematology parameters between the CKD‐501‐treated groups and their corresponding controls, but the histopathological evidence did not reveal any findings attributed to CKD‐501. Treated animals exhibited non‐neoplastic findings (adipocyte proliferation, bone marrow hypoplasia cardiomyopathy), but all of these were expected changes for this class of compound. There were no treatment‐related neoplastic changes in this study. The results of this study therefore demonstrate a lack of carcinogenicity following oral administration of CKD‐501 to ICR mice for 104 weeks. Copyright © 2013 John Wiley & Sons, Ltd.
- 1 July 2013
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 79 (11) , 959-962
Assessment of Dermal Safety of Scutellaria baicalensis Aqueous Extract Topical Application on Skin Hypersensitivity
Scutellaria baicalensis has been used as a traditional herbal medicine for bronchitis, hepatitis, and allergic diseases. The root of Scutellaria baicalensis contains active flavonoid components, including baicalin, baicalein, wogonoside, and wogonin, which have pharmaceutical properties. In the present study, the antiallergic properties of a standardized aqueous extract of S. baicalensis were evaluated, and the skin toxicity of its dermal application was also determined. The in vivo and in vitro assays were performed by using the β-hexosaminidase assay in rat basophilic leukemia cells (RBL-2H3) and cutaneous skin reaction in BALB/c mice, respectively. In addition, the acute dermal irritation/corrosion test was carried out in New Zealand white rabbits, and the skin sensitization test was conducted by Buhlerʼs method in Hartley guinea pigs to estimate the safety of the standardized aqueous extract of S. baicalensis for topical application. β-Hexosaminidase release in RBL-2H3 was markedly decreased following treatment with the standardized aqueous extract of S. baicalensis. It also ameliorated antigen-induced ear swelling compared with the control group in BALB/c mice. In the toxicological studies, it did not induce any dermal irritation/corrosion in rabbits or skin sensitization in guinea pigs. Although still limited, these results concerning the toxicological effects of S. baicalensis could be an initial step toward the topical application of S. baicalensis extracts on hypersensitive skin.
- 1 July 2013
- Published by Georg Thieme Verlag KG in Planta Medica
- Vol. 79 (11) , 959-962
Assessment of Dermal Safety of Scutellaria baicalensis Aqueous Extract Topical Application on Skin Hypersensitivity
Scutellaria baicalensis has been used as a traditional herbal medicine for bronchitis, hepatitis, and allergic diseases. The root of Scutellaria baicalensis contains active flavonoid components, including baicalin, baicalein, wogonoside, and wogonin, which have pharmaceutical properties. In the present study, the antiallergic properties of a standardized aqueous extract of S. baicalensis were evaluated, and the skin toxicity of its dermal application was also determined. The in vivo and in vitro assays were performed by using the β-hexosaminidase assay in rat basophilic leukemia cells (RBL-2H3) and cutaneous skin reaction in BALB/c mice, respectively. In addition, the acute dermal irritation/corrosion test was carried out in New Zealand white rabbits, and the skin sensitization test was conducted by Buhlerʼs method in Hartley guinea pigs to estimate the safety of the standardized aqueous extract of S. baicalensis for topical application. β-Hexosaminidase release in RBL-2H3 was markedly decreased following treatment with the standardized aqueous extract of S. baicalensis. It also ameliorated antigen-induced ear swelling compared with the control group in BALB/c mice. In the toxicological studies, it did not induce any dermal irritation/corrosion in rabbits or skin sensitization in guinea pigs. Although still limited, these results concerning the toxicological effects of S. baicalensis could be an initial step toward the topical application of S. baicalensis extracts on hypersensitive skin.
- 4 October 2012
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 50 (12) , 1473-1478
Protective effect of the aqueous extract from the root ofPlatycodon grandiflorumon cholestasis-induced hepatic injury in mice
Context: The root of Platycodon grandiflorum (Jacq.) A. DC. (Campanulaceae) has been widely studied for its hepatoprotective effects against various hepatotoxicants. Objective: The present study evaluated the protective effect of the standardized aqueous extract of P. grandiflorum (BC703) on cholestasis-induced hepatic injury in mice. Materials and methods: BC703 is a standardized aqueous extract of P. grandiflorum in reference to platycodin D (at least 0.8%). The mice were allocated into five groups as follows: Sham-operated, bile duct ligation (BDL) alone, and BDL with BC703 (1, 5, and 10 mg/kg BW) treated group. BC703 was given for 3 consecutive days before BDL operation. The animals were sacrificed by CO2 anesthesia post-24 h of BDL operations. Results and discussion: Serum alanine aminotransferase and serum aspartate aminotransferase increased to 395.2 ± 90.0 and 266.0 ± 45.6 Unit/L in the BDL alone group and decreased with BC703 in a dose-dependent manner. Especially the 10 mg/kg of BC703-treated mice showed a 77% decrease of serum alanine aminotransferase and 56% of aspartate aminotransferase as compared with BDL alone. Decreased antioxidant enzyme levels in BDL alone group were elevated in BC703-treated groups ranging from 7 to 29% for glutathione and from 13 to 25% for superoxide dismutase. BC703 treatment also attenuated malondialdehyde (from 3 to 32%) and nitric oxide levels (from 32 to 50%) as compared with BDL alone. Histopathological studies further confirmed the hepatoprotective effect of BC703 in BDL-induced cholestesis. Conclusion: BC703 could attenuate liver injury by BDL in mice, and test results indicate that BC703 might be useful in cholestatic liver injury.
- 4 October 2012
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 50 (12) , 1473-1478
Protective effect of the aqueous extract from the root ofPlatycodon grandiflorumon cholestasis-induced hepatic injury in mice
Context: The root of Platycodon grandiflorum (Jacq.) A. DC. (Campanulaceae) has been widely studied for its hepatoprotective effects against various hepatotoxicants. Objective: The present study evaluated the protective effect of the standardized aqueous extract of P. grandiflorum (BC703) on cholestasis-induced hepatic injury in mice. Materials and methods: BC703 is a standardized aqueous extract of P. grandiflorum in reference to platycodin D (at least 0.8%). The mice were allocated into five groups as follows: Sham-operated, bile duct ligation (BDL) alone, and BDL with BC703 (1, 5, and 10 mg/kg BW) treated group. BC703 was given for 3 consecutive days before BDL operation. The animals were sacrificed by CO2 anesthesia post-24 h of BDL operations. Results and discussion: Serum alanine aminotransferase and serum aspartate aminotransferase increased to 395.2 ± 90.0 and 266.0 ± 45.6 Unit/L in the BDL alone group and decreased with BC703 in a dose-dependent manner. Especially the 10 mg/kg of BC703-treated mice showed a 77% decrease of serum alanine aminotransferase and 56% of aspartate aminotransferase as compared with BDL alone. Decreased antioxidant enzyme levels in BDL alone group were elevated in BC703-treated groups ranging from 7 to 29% for glutathione and from 13 to 25% for superoxide dismutase. BC703 treatment also attenuated malondialdehyde (from 3 to 32%) and nitric oxide levels (from 32 to 50%) as compared with BDL alone. Histopathological studies further confirmed the hepatoprotective effect of BC703 in BDL-induced cholestesis. Conclusion: BC703 could attenuate liver injury by BDL in mice, and test results indicate that BC703 might be useful in cholestatic liver injury.
- 26 May 2011
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 34 (6) , 618-620
Pharmacokinetics and bioavailability of cefquinome in rabbits following intravenous and intramuscular administration
- 26 May 2011
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 34 (6) , 618-620
Pharmacokinetics and bioavailability of cefquinome in rabbits following intravenous and intramuscular administration
- Open Access
- 1 January 2011
- Published by Japanese Society of Toxicologic Pathology in Journal of Toxicologic Pathology
- Vol. 24 (4) , 223-228
Protective Effects of Platycodon grandiflorum AqueousExtract on Thioacetamide-induced Fulminant HepaticFailure in Mice
The aim of the present study was to evaluate the protective activity of aqueous extract from Platycodon grandiflorum (BC703) on thioacetamide (TA)-induced hepatotoxicity in mice. We found that BC703 significantly decreased mortality and the change in serum transaminase following TA administration. The group treated with BC703 at doses of 1, 5, and 10 mg/kg produced significant hepatoprotective effects against TA-induced liver damage by decreasing the activities of serum enzymes, nitric oxide and lipid peroxidation in dose-dependent manners. Histopathological studies further substantiated the protective effect of BC703. These results show the hepatoprotective activity of aqueous extract from Platycodon grandiflorum on thioacetamide-induced fulminant hepatic failure.
- 1 January 2011
- Published by Japanese Society of Toxicologic Pathology in Journal of Toxicologic Pathology
- Vol. 24 (4) , 223-228
Open AccessProtective Effects of Platycodon grandiflorum AqueousExtract on Thioacetamide-induced Fulminant HepaticFailure in Mice
The aim of the present study was to evaluate the protective activity of aqueous extract from Platycodon grandiflorum (BC703) on thioacetamide (TA)-induced hepatotoxicity in mice. We found that BC703 significantly decreased mortality and the change in serum transaminase following TA administration. The group treated with BC703 at doses of 1, 5, and 10 mg/kg produced significant hepatoprotective effects against TA-induced liver damage by decreasing the activities of serum enzymes, nitric oxide and lipid peroxidation in dose-dependent manners. Histopathological studies further substantiated the protective effect of BC703. These results show the hepatoprotective activity of aqueous extract from Platycodon grandiflorum on thioacetamide-induced fulminant hepatic failure.
- Open Access
- 1 January 2011
- Published by XMLink in Journal of Veterinary Science
- Vol. 12 (2) , 115-119
In vivometabolism of Talosin A, new isoflavonol glycoside fromKitasatospora kifunensis, in rats
Lim JH, et al. J Vet Sci. 2011 Jun;12(2):115-119. http://dx.doi.org/10.4142/jvs.2011.12.2.115
- 1 January 2011
- Published by XMLink in Journal of Veterinary Science
- Vol. 12 (2) , 115-119
Open AccessIn vivometabolism of Talosin A, new isoflavonol glycoside fromKitasatospora kifunensis, in rats
Lim JH, et al. J Vet Sci. 2011 Jun;12(2):115-119. http://dx.doi.org/10.4142/jvs.2011.12.2.115
- 28 December 2010
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 34 (2) , 206-208
Pharmacokinetics of florfenicol following intramuscular and intravenous administration in olive flounder (Paralichthys olivaceus)
- 28 December 2010
- Published by Wiley in Journal of Veterinary Pharmacology and Therapeutics
- Vol. 34 (2) , 206-208
Pharmacokinetics of florfenicol following intramuscular and intravenous administration in olive flounder (Paralichthys olivaceus)
- 11 July 2010
- Published by Elsevier in Aquaculture
- Vol. 307 (1-2) , 71-74
Plasma and tissue depletion of florfenicol in olive flounder (Paralichthys olivaceus) after oral administration
- 11 July 2010
- Published by Elsevier in Aquaculture
- Vol. 307 (1-2) , 71-74
Plasma and tissue depletion of florfenicol in olive flounder (Paralichthys olivaceus) after oral administration